https://i.imgflip.com/94i584.jpg

‘Adding’ to the Jurisprudence: Assistant Controller’s Analyses on the Ayyangar Committee’s Reservations to the Swan Committee for Patent of Addition

/ By / Patent

It is rather tragic that very few Controllers in India write sufficiently detailed and reasoned decisions, and the position is even dismal when one hopes to come across well-analysed jurisprudential orders for patent grants/rejections. To narrow this down further in scope, let’s take ‘patents of addition.’ By themselves, these have not attracted much limelight. The last major highlight that I can recall was regarding the applicability of Section 39 on patents of addition in the Selfdot case (covered nicely by […]

‘Adding’ to the Jurisprudence: Assistant Controller’s Analyses on the Ayyangar Committee’s Reservations to the Swan Committee for Patent of Addition Read More »

SpicyIP Weekly Review (September 30-October 6)

/ By / Copyright, Drug Regulation, Innovation, Patent, Trademark

Here is our recap of last week’s top IP developments including summary of the posts on the Lenacapavir patent application and oppositions, ANRF and corporatisation of research, the copyright dispute between Jasleen Royal and T Series, and DHC’s recent order in Master Arnesh Shaw v. Union of India This and a lot more in this week’s SpicyIP Weekly Review. Anything we are missing out on? Drop a comment below to let us know.  Highlights of the Week Patent Application for

SpicyIP Weekly Review (September 30-October 6) Read More »

https://i.imgflip.com/95hi7k.jpg

A Followup on Lenacapavir: Gilead enters into Voluntary Licensing Agreements in 120 LMICs

/ By / Drug Regulation, Patent

Just a day after our update on the Lenacapavir patent oppositions (here), Gilead has signed “Royalty-Free Voluntary Licensing Agreements” (VLAs) (pdf) with generic manufacturers aimed at boosting HIV prevention in “high-incidence, resource-limited countries.” The focus is squarely on low- and middle-income countries (LMICs), as highlighted in Gilead’s official reports (here) and various media outlets (here). This strategic move reflects Gilead’s commitment to expanding access to vital treatments where they’re needed most, and this post will fact-check the coverage of these

A Followup on Lenacapavir: Gilead enters into Voluntary Licensing Agreements in 120 LMICs Read More »

Funding the Future: How the ANRF’s Skewed Approach has Reignited the Debate on the Corporatisation of Research

/ By / Innovation

The launch of the Anusandhan National Research Foundation (ANRF) and its emphasis on private funding in R&D has led to concerns over the corporatisation of research. In this detailed post, Samridhi Chugh explores the implications of this shift in government approach, its impact on curiosity-driven research and what India can learn from the world in forging successful industry-academia partnerships. Samridhi is a final-year student at the Campus Law Centre, Faculty of Law, University of Delhi, and a graduate in Journalism

Funding the Future: How the ANRF’s Skewed Approach has Reignited the Debate on the Corporatisation of Research Read More »

SpicyIP Tidbit: An Update on Master Arnesh Shaw v. Union of India-Delhi High Court Holds Sarepta Accountable for Delays and MoHFW Ordered to Release Funds

/ By / Patent

[This post has been authored by SpicyIP intern Mehnaz Khatoon. Mehnaz is a recent law graduate from Aligarh Muslim University Centre Malappuram. She is passionate about Intellectual Property Laws and is interested in pursuing a career in the corporate sector. Her previous posts can be accessed here.] In a crucial order in the Master Arnesh Shaw vs. Union of India & Anr on 13th September 2024, the Delhi High Court took a firm stand in the ongoing legal battle concerning the

SpicyIP Tidbit: An Update on Master Arnesh Shaw v. Union of India-Delhi High Court Holds Sarepta Accountable for Delays and MoHFW Ordered to Release Funds Read More »

https://www.eatg.org/wp-content/uploads/2023/01/lenacapavir.webp

Patent Application for Gilead’s Lenacapavir Opposed: Saving Generics of HIV Drugs?

/ By / Others

[A big thanks to Swaraj for his inputs on the post.] The Indian Patent Office (IPO) is set to hear objections against Gilead Sciences’ patent claims for Lenacapavir, an HIV drug. This situation highlights the ongoing struggle between patent protections and access to essential medicines. Pre-grant oppositions (PGOs) are crucial in India’s patent system, allowing challenges to patents before they’re granted. The outcome could significantly affect the availability of affordable HIV treatments, emphasising the need to balance innovation with public

Patent Application for Gilead’s Lenacapavir Opposed: Saving Generics of HIV Drugs? Read More »

[Sponsored] Registration Deadline Extended for the “Comprehensive Course on Patents” Organized by The IP Press In Collaboration with S. Majumdar & Co. (October 5-November 23)

/ By / Sponsored

We are pleased to bring to you this sponsored post by IP Press on the extension of the registration deadlines for their Comprehensive Course on Patents, in collaboration with S. Majumdar & Co. The deadline for registration has now been extended to October 4. For more details, read their announcement below: Registration Deadline Extended for the “Comprehensive Course on Patents” Organized by The IP Press In Collaboration with S. Majumdar & Co. (October 5-November 23) Following a favorable outcome of

[Sponsored] Registration Deadline Extended for the “Comprehensive Course on Patents” Organized by The IP Press In Collaboration with S. Majumdar & Co. (October 5-November 23) Read More »

Comments Invited for Amendments to the Geographical Indications of Goods (Registration and Protection) Act, 1999, by October 10

/ By / Geographical Indication

[This post is authored by SpicyIP Intern Samridhi Chugh. Samridhi is a final-year student at the Campus Law Centre, Faculty of Law, University of Delhi, and a graduate in Journalism from Lady Shri Ram College for Women. With a passion for the dynamic intersection of law, media and technology, she is particularly interested in exploring intellectual property and tech policy. Her previous posts can be accessed here.] The Ministry of Commerce and Industry, in a public notice, dated September 27, 2024,

Comments Invited for Amendments to the Geographical Indications of Goods (Registration and Protection) Act, 1999, by October 10 Read More »

SpicyIP Tidbit: Bombay High Court Strikes Down the Controversial IT Amendment Rules for Setting up Fact Check Units

/ By / Others

Discussing the Bombay High Court’s recent decision that set aside the controversial IT Rules amendments to establish fact check units, we are pleased to bring to you this tidbit by SpicyIP intern Mehnaz Khatoon. Mehnaz is a recent law graduate from Aligarh Muslim University Centre Malappuram. She is passionate about Intellectual Property Laws and is interested in pursuing a career in the corporate sector. Her previous post can be accessed here. SpicyIP Tidbit: Bombay High Court Strikes Down the Controversial

SpicyIP Tidbit: Bombay High Court Strikes Down the Controversial IT Amendment Rules for Setting up Fact Check Units Read More »

“All Right” for Who? Assessing the Jasleen Royal and T-Series Recent Copyright Controversy

/ By / Copyright

In light of the recent copyright dispute between singer Jasleen Royal and music label T-Series over the composition of the song “All Right”, we are pleased to bring to you this quick post by SpicyIP intern Mansi Bhatia. Mansi is a fifth-year law student at the Institute of Law, Nirma University, with a keen interest in IP Law and Data Protection Law. “All Right” for Who? Assessing the Jasleen Royal and T-Series Recent Copyright Controversy By Mansi Bhatia It’s not

“All Right” for Who? Assessing the Jasleen Royal and T-Series Recent Copyright Controversy Read More »

Scroll to Top